SUCAMPO PHARM 'A' : Sucampo to Release First Quarter 2011 Financial Results and to Conduct a Conference Call on May 10, 2011
05/03/2011| 04:15pm US/Eastern
Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) today announced that it
will sponsor a conference call to discuss its financial results for the
first quarter of 2011 ended March 31, 2011. These results are expected
to be released on Tuesday, May 10, 2011, after the capital markets
close. The conference call will be hosted by senior management and will
be held at 5:00 pm Eastern on Tuesday, May 10, 2011.
Investors may listen to the live call by dialing 866-783-2138 (domestic)
or 1-857-350-1597 (international), passcode 43306772 five to ten minutes
ahead of the start of the call. A replay of the call will be available
within a few hours after the call ends. Investors may listen to the
replay by dialing 888-286-8010 (domestic) or 1-617-801-6888
(international), passcode 55806927.
The conference call will be webcast and may be accessed at the "For
Investors" section of the company's website, www.sucampo.com.
Investors interested in listening to the live audio webcast should log
on before the conference call begins in order to download any software
required. The archive of the conference call will remain available for
About Sucampo Pharmaceuticals
Sucampo Pharmaceuticals, Inc., an international pharmaceutical company
based in Bethesda, Maryland, is focused on the discovery, development
and commercialization of proprietary drugs based on prostones. Prostones
are a class of compounds that occur naturally in the human body as a
result of enzymatic, 15-PGDH, transformation of certain fatty acids. The
therapeutic potential of prostones was first identified by Dr. Ryuji
Ueno, Sucampo's Chairman and Chief Executive Officer. He founded Sucampo
Pharmaceuticals in 1996 with Dr. Sachiko Kuno, founding Chief Executive
Officer and currently Executive Advisor, International Business
Development, and a member of the Board of Directors. For more
information about Sucampo Pharmaceuticals, please visit www.sucampo.com.
Any statements in this press release about future expectations, plans
and prospects for Sucampo Pharmaceuticals are forward-looking statements
made under the provisions of The Private Securities Litigation Reform
Act of 1995. Forward-looking statements may be identified by the words
"project," "believe," "anticipate," "plan," "expect," "estimate,"
"intend," "should," "would," "could," "will," "may" or other similar
expressions. Actual results may differ materially from those indicated
by such forward-looking statements as a result of various important
factors, including those described in Sucampo Pharmaceuticals' filings
with the Securities and Exchange Commission (SEC), including the annual
report on Form 10-K for the year ended December 31, 2010, and other
periodic reports filed with the SEC. Any forward-looking statements in
this press release represent Sucampo's views only as of the date of this
release and should not be relied upon as representing its views as of
any subsequent date. Sucampo does not undertake any obligation to update
any forward-looking statements contained in this release as a result of
new information, future events or otherwise, except as required by law.
Sucampo Pharmaceuticals, Inc.
Kate de Santis, 240-223-3834
© Business Wire 2011